Histology
Carcinoma of Unknown Primary
CI-CAN-00002109Explore in graph →
4,151 active trials54 approved drugs532 evidence items
Loading cancer entity…
Histology
CI-CAN-00002109Explore in graph →
Clinical trials
14,225 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,893)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06306560 | A Study of Adebrelimab Combined With Famitinib and Chemotherapy in the Treatment of ES-SCLC. | not yet recruiting | Phase 2 | 40 | Harbin Medical UniversityOTHER | 0 | Mar 12, 2024 | clinicaltrials |
| NCT06253598 | Efficacy and Safety of Intratumoral Injection of Recombinant Human Adenovirus Type 5 Combined With Tislelizumab and Lenvatinib in the Treatment of Advanced Hepatocellular Carcinoma | not yet recruiting | Phase 2 | 30 | The First Affiliated Hospital of Bengbu Medical UniversityOTHER | 0 |
| Mar 7, 2024 |
| clinicaltrials |
| NCT06297811 | Myeloprotection With Trilaciclib in Pan-cancer Population | not yet recruiting | Phase 2 | 132 | Sun Yat-sen UniversityOTHER | 1 | Mar 7, 2024 | clinicaltrials |
| NCT06236997 | Adebrelimab and Concurrent Radiochemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer | not yet recruiting | Phase 2 | 48 | Henan Cancer HospitalOTHER_GOV | 1 | Feb 1, 2024 | clinicaltrials |
| NCT06229067 | Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With Metronomic VEX in Advanced Triple-negative Breast Cancer | not yet recruiting | Phase 2 | 182 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Jan 29, 2024 | clinicaltrials |
| NCT06066216 | Cadonilimab (AK104) Plus Chemotherapy in Patients With Recurrent or Advanced Endometrial Cancer | not yet recruiting | Phase 2 | 45 | Fujian Cancer HospitalOTHER_GOV | 0 | Jan 23, 2024 | clinicaltrials |
| NCT06199271 | Neoadjuvant Adebrelimab Plus Dalpiciclib in Head and Neck Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 30 | Zhongzheng XiangOTHER | 0 | Jan 22, 2024 | clinicaltrials |
| NCT06202313 | Study of Cadonilimab (AK104) Plus Eribulin vs. Eribulin Monotherapy for Recurrent or Metastatic Triple-negative Breast Cancer | not yet recruiting | Phase 2 | 128 | Shengjing HospitalOTHER | 1 | Jan 11, 2024 | clinicaltrials |
| NCT06196775 | A Study of Cadonilimab Combined With AK112 as Second-line Therapy in Patients With Advanced Hepatocellular Carcinoma | not yet recruiting | Phase 2 | 36 | Harbin Medical UniversityOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT06195670 | Clinical Study of Short-course Radiotherapy Followed by Fruquintinib Plus Sintilimab vs Bevacizumab Plus Capecitabine as First Line Treatment in Advanced mCRC | not yet recruiting | Phase 1 / Phase 2 | 220 | Zhejiang Cancer HospitalOTHER | 1 | Jan 8, 2024 | clinicaltrials |
| NCT04889742 | Hyperthermia Enhanced Re-irradiation of Loco-regional Recurrent Tumors(HETERERO) | not yet recruiting | Phase 2 | 110 | Charite University, Berlin, GermanyOTHER | 1 | Dec 26, 2023 | clinicaltrials |
| NCT06178211 | Neoadjuvant Adebrelimab Plus Chemotherapy for Resectable ESCC: a Single Arm, Prospective Phase 2 Clinical Trial | not yet recruiting | Phase 2 | 36 | Shanghai Chest HospitalOTHER | 1 | Dec 20, 2023 | clinicaltrials |
| NCT06121271 | Trial of Lu-177 DOTATATE (Lutathera®) in Unlicensed Indications | not yet recruiting | Phase 2 | 110 | University College, LondonOTHER | 0 | Dec 7, 2023 | clinicaltrials |
| NCT06152978 | A Perioperative Sintilimab and Chemotherapy in Esophageal Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 182 | Fudan UniversityOTHER | 1 | Dec 1, 2023 | clinicaltrials |
| NCT06086288 | Study of PembrolizumAb combiNeD With Cisplatin or carbOplatin and Etoposide in Treatment naïve Advanced meRkel Cell cArcinoma (MCC)(PANDORA) | not yet recruiting | Phase 2 | 35 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Oct 17, 2023 | clinicaltrials |
| NCT03865277 | Individualized Radiation Dose Prescription in HNSCC Based on F-MISO-PET Hypoxia-Imaging(INDIRA-MISO) | not yet recruiting | Phase 2 | 276 | Technische Universität DresdenOTHER | 1 | Sep 11, 2023 | clinicaltrials |
| NCT06016413 | Adelbelimab Combination Chemotherapy in Neoadjuvant Therapy for Squamous Cell Carcinoma of the Head and Neck | not yet recruiting | Phase 2 | 30 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Aug 29, 2023 | clinicaltrials |
| NCT05993858 | Neoadjuvant PD-1 Inhibitor Combined With Cetuximab in Operable Locally Advanced HNSCC(PC-1) | not yet recruiting | Phase 2 | 33 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Aug 15, 2023 | clinicaltrials |
| NCT05976568 | A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma | not yet recruiting | Phase 2 / Phase 3 | 668 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 4, 2023 | clinicaltrials |
| NCT05970627 | Perioperative Chemotherapy Plus Toripalimab for Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma | not yet recruiting | Phase 2 | 30 | Yu jirenOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT05897138 | A Study to Evaluate Lenvatinib Plus Tislelizumab for Locally Advanced Unresectable or Metastatic Hepatocellular Carcinoma With Hepatitis B Virus Infection and Biomarker Analyses | not yet recruiting | Phase 2 | 30 | Fujian Cancer HospitalOTHER_GOV | 0 | Jun 13, 2023 | clinicaltrials |
| NCT05286320 | Phase Ib/II Trial of Combining Pembrolizumab and Lenvatinib With SBRT for HCC Patients With Portal Vein Thrombosis. | not yet recruiting | Phase 1 / Phase 2 | 27 | National Taiwan University HospitalOTHER | 1 | Mar 2, 2023 | clinicaltrials |
| NCT05732662 | SBRT Combined With AK104 to Treatment Relapsed or Metastatic ESCC | not yet recruiting | Phase 2 | 25 | The First People's Hospital of ChangzhouOTHER | 0 | Feb 17, 2023 | clinicaltrials |
| NCT05703997 | FASTing-like Approach and Maintenance IMMunotherapy in ES-SCLC Patients Not Progressing on Chemoimmunotherapy Induction(FASTIMMUNE) | not yet recruiting | Phase 2 | 20 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Jan 30, 2023 | clinicaltrials |
| NCT05484583 | Durvalumab Combined With Consolidation Radiotherapy After First-line Treatment in Extensive Stage Small Cell Lung Cancer With Oligometastases | not yet recruiting | Phase 2 | 58 | Affiliated Cancer Hospital & Institute of Guangzhou Medical UniversityOTHER | 0 | Aug 5, 2022 | clinicaltrials |
| NCT05067530 | Cyclin dEpendent Kinase in tRiple nEGatIVe brEast canceR - a "Window of Opportunity" Study(CAREGIVER) | not yet recruiting | Phase 2 | 126 | Medical University of GdanskOTHER | 1 | Oct 5, 2021 | clinicaltrials |
| NCT04158856 | Adjuvant Dual Anti-HER2 Therapy in Patients With Small, Node-negative, HER2-positive Breast Cancer(SHERO) | not yet recruiting | Phase 2 | 60 | xuexin heOTHER | 0 | Nov 12, 2019 | clinicaltrials |
| NCT02490735 | CIK in Treating Patients With Esophageal Cancer | not yet recruiting | Phase 2 | 2,000 | The First People's Hospital of ChangzhouOTHER | 0 | Jul 7, 2015 | clinicaltrials |
Data updated 22 days agoSource updated Mar 12, 2024source: clinicaltrials